Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression

Vaccine

Volumn 33, Issue 43, 2015, Pages 5838-5844

  Neumann, Silke ^a,b   Young, Katie ^a,b   Compton, Benji ^c   Anderson, Regan ^c   Painter, Gavin ^c   Hook, Sarah ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

Cancer vaccines; Invariant natural killer T cells; Liposomes; Long peptides; Melanoma; Galactosylceramide

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DOPACHROME TAUTOMERASE; GAMMA INTERFERON; INTERLEUKIN 2; LIPOSOME; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ALPHA-GALACTOSYLCERAMIDE; DOPACHROME ISOMERASE; GALACTOSYLCERAMIDE; IMMUNOLOGIC FACTOR; ISOMERASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; IN VITRO STUDY; MELANOMA; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TUMOR GROWTH; TUMOR IMMUNITY; ANIMAL; C57BL MOUSE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; SECRETION (PROCESS); SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; GALACTOSYLCERAMIDES; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; INTRAMOLECULAR OXIDOREDUCTASES; LIPOSOMES; MELANOMA; MICE, INBRED C57BL; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 84944035926     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.083     Document Type: Article

References (44)

1. Palucka K., Ueno H., Banchereau J. Recent developments in cancer vaccines. J Immunol 2011, 186(3):1325-1331.
2. Klebanoff C.A., Acquavella N., Yu Z., Restifo N.P. Therapeutic cancer vaccines: are we there yet?. Immunol Rev 2011, 239(1):27-44.
3. Blanchard T., Srivastava P.K., Duan F. Vaccines against advanced melanoma. Clin Dermatol 2013, 31(2):179-190.
4. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011, 12(6):509-517.
5. Toes R.E., Offringa R., Blom R.J., Melief C.J., Kast W.M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A 1996, 93(15):7855-7860.
6. Bijker M.S., van den Eeden S.J., Franken K.L., Melief C.J., van der Burg S.H., Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged. DC-focused antigen presentation. Eur J Immunol 2008, 38(4):1033-1042.
7. Berzofsky J.A., Terabe M. The contrasting roles of NKT cells in tumor immunity. Curr Mol Med 2009, 9(6):667-672.
8. Brigl M., Brenner M.B. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004, 22:817-890.
9. Nagarajan N.A., Kronenberg M. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol (Baltim MD: 1950) 2007, 178(5):2706-2713.
10. Smyth M.J., Crowe N.Y., Godfrey D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001, 13(4):459-463.
11. Smyth M.J., Crowe N.Y., Pellicci D.G., Kyparissoudis K., Kelly J.M., Takeda K., et al. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 2002, 99(4):1259-1266.
12. Hermans I.F., Silk J.D., Gileadi U., Salio M., Mathew B., Ritter G., et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003, 171(10):5140-5147.
13. Schneiders F.L., Scheper R.J., von Blomberg B.M.E., Woltman A.M., Janssen H.L.A., van den Eertwegh A.J.M., et al. Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol 2011, 140(2):130-141.
14. Petersen T.R., Sika-Paotonu D., Knight D.A., Dickgreber N., Farrand K.J., Ronchese F., et al. Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand. Immunol Cell Biol 2010, 88(5):596-604.
15. Boileau C., Pelletier J.P., Tardif G., Fahmi H., Laufer S., Lavigne M., et al. The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway. Ann Rheum Dis 2005, 64(6):891-898.
16. Fujii S.-i., Shimizu K., Hemmi H., Fukui M., Bonito A.J., Chen G., et al. Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci 2006, 103(30):11252-11257.
17. Fujii S., Shimizu K., Smith C., Bonifaz L., Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003, 198(2):267-279.
18. Nakamura T., Yamazaki D., Yamauchi J., Harashima H. The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration. J Control Release 2013, 171(2):216-224.
19. Cerundolo V., Silk J.D., Masri S.H., Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009, 9(1):28-38.
20. Thapa P., Zhang G., Xia C., Gelbard A., Overwijk W.W., Liu C., et al. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 2009, 27(25-26):3484-3488.
21. Bramwell V.W., Perrie Y. Particulate delivery systems for vaccines: what can we expect?. J Pharm Pharmacol 2006, 58(6):717-728.
22. Yan W., Chen W., Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase ERK and induction of chemokines. Mol Immunol 2007, 44(15):3672-3681.
23. Yan W., Chen W., Huang L. Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J Control Release 2008, 130(1):22-28.
24. Vangasseri D.P., Cui Z., Chen W., Hokey D.A., Falo L.D., Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol 2006, 23(5):385-395.
25. Oussoren C., Zuidema J., Crommelin D.J., Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta 1997, 1328(2):261-272.
26. Kaur R., Bramwell V.W., Kirby D.J., Perrie Y. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses. J Control Release 2012, 158(1):72-77.
27. Bloom M.B., Perry-Lalley D., Robbins P.F., Li Y., el-Gamil M., Rosenberg S.A., et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997, 185(3):453-459.
28. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965, 13(1):238-252.
29. Du W., Gervay-Hague J. Efficient synthesis of alpha-galactosyl ceramide analogues using glycosyl iodide donors. Org Lett 2005, 7(10):2063-2065.
30. Konnings S., Copland M.J., Davies N.M., Rades T. A method for the incorporation of ovalbumin into immune stimulating complexes prepared by the hydration method. Int J Pharm 2002, 241(2):385-389.
31. Hubert M., Larsen D.S., Hayman C.M., Rades T., Hook S. Physical characterization of synthetic phosphatidylinositol dimannosides and analogues in binary systems with phosphatidylcholine. Mol Pharm 2014, 11(3):913-921.
32. Fuertes Marraco S.A., Grosjean F., Duval A., Rosa M., Lavanchy C., Ashok D., et al. Novel murine dendritic cell lines: a powerful auxiliary tool for dendritic cell research. Front Immunol 2012, 3.
33. Lantz O., Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 1994, 180(3):1097-1106.
34. Kojarunchitt T., Baldursdottir S., Dong Y.-D., Boyd B.J., Rades T., Hook S. Modified thermoresponsive Poloxamer 407 and chitosan sol-gels as potential sustained-release vaccine delivery systems. Eur J Pharm Biopharm 2015, 89:74-81.
35. Ko Y.T., Falcao C., Torchilin V.P. Cationic liposomes loaded with proapoptotic peptide d-(KLAKLAK)2 and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol Pharm 2009, 6(3):971-977.
36. Barnier-Quer C., Elsharkawy A., Romeijn S., Kros A., Jiskoot W. Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators. Pharmaceutics 2013, 5(3):392-410.
37. Henriksen-Lacey M., Christensen D., Bramwell V.W., Lindenstrom T., Agger E.M., Andersen P., et al. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA) 3beta-[N-(N',N'-dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. Mol Pharm 2011, 8(1):153-161.
38. Bendelac A., Lantz O., Quimby M.E., Yewdell J.W., Bennink J.R., Brutkiewicz R.R. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995, 268(5212):863-865.
39. Melief C.J.M., van der Burg S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008, 8(5):351-360.
40. Courtney A.N., Nehete P.N., Nehete B.P., Thapa P., Zhou D., Sastry K.J. Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine 2009, 27(25-26):3335-3341.
41. Gonzalez-Aseguinolaza G., Van Kaer L., Bergmann C.C., Wilson J.M., Schmieg J., Kronenberg M., et al. Cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002, 195(5):617-624.
42. Tsai C.C., Chang C.H., Chen L.C., Chang Y.J., Lan K.L., Wu Y.H., et al. Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. Int J Nanomed 2011, 6:2607-2619.
43. McKee S.J., Young V.L., Clow F., Hayman C.M., Baird M.A., Hermans I.F., et al. Virus-like particles and alpha-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses. J Control Release 2012, 159(3):338-345.
44. Bourquin C., Anz D., Zwiorek K., Lanz A.L., Fuchs S., Weigel S., et al. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol 2008, 181(5):2990-2998.